IMCR – Immunocore Holdings plc ADR
Immunocore Holdings plcIMCR
$28.41Name : Immunocore Holdings plc
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,401,908,480.00
EPSttm : -1.02
Immunocore Holdings plc
$28.41
1.94%$0.54Float Short %
16.59
Margin Of Safety %
-27
Put/Call OI Ratio
2.04
EPS Next Q Diff
0.07
EPS Last/This Y
-0.59
EPS This/Next Y
-0.4
Price
28.41
Target Price
63.84
Analyst Recom
1.71
Performance Q
-2.37
Relative Volume
0.61
Beta
0.76
Ticker: IMCR
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-20 | IMCR | 30.48 | 0.54 | 0.00 | 6804 |
| 2025-03-21 | IMCR | 29.85 | 0.53 | 0.25 | 6847 |
| 2025-03-24 | IMCR | 29.69 | 0.47 | 0.00 | 2914 |
| 2025-03-25 | IMCR | 29.32 | 0.47 | 5.00 | 2924 |
| 2025-03-26 | IMCR | 29.51 | 0.47 | 0.33 | 2928 |
| 2025-03-27 | IMCR | 30.13 | 0.47 | 0.92 | 2940 |
| 2025-03-28 | IMCR | 29.58 | 0.53 | 1.33 | 3520 |
| 2025-03-31 | IMCR | 29.7 | 0.53 | 21.50 | 3526 |
| 2025-04-01 | IMCR | 28.69 | 0.55 | 5.00 | 3565 |
| 2025-04-02 | IMCR | 29.44 | 0.55 | 0.00 | 3569 |
| 2025-04-03 | IMCR | 29 | 0.55 | 0.50 | 3569 |
| 2025-04-04 | IMCR | 27.2 | 0.55 | 3.50 | 3567 |
| 2025-04-07 | IMCR | 26.25 | 0.54 | 0.67 | 3582 |
| 2025-04-08 | IMCR | 24.53 | 0.54 | 178.71 | 3583 |
| 2025-04-09 | IMCR | 26.01 | 1.61 | 1.96 | 6088 |
| 2025-04-10 | IMCR | 25.85 | 1.45 | 999.99 | 6336 |
| 2025-04-11 | IMCR | 26.58 | 1.45 | 999.99 | 6336 |
| 2025-04-14 | IMCR | 26.75 | 2.42 | 0.00 | 8836 |
| 2025-04-15 | IMCR | 27.25 | 2.15 | 2.00 | 9166 |
| 2025-04-16 | IMCR | 27.9 | 1.98 | 60.00 | 9441 |
| 2025-04-17 | IMCR | 28.42 | 2.04 | 0.40 | 9601 |
| 2025-04-18 | IMCR | 28.41 | 2.04 | 0.40 | 9601 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-20 | IMCR | 30.43 | 34.9 | -76.0 | -1.63 |
| 2025-03-21 | IMCR | 29.93 | 34.9 | -65.5 | -1.63 |
| 2025-03-24 | IMCR | 29.64 | 34.9 | -66.7 | -1.63 |
| 2025-03-25 | IMCR | 29.32 | 34.9 | -66.4 | -1.63 |
| 2025-03-26 | IMCR | 29.47 | 34.9 | -68.7 | -1.63 |
| 2025-03-27 | IMCR | 30.09 | 34.9 | -71.0 | -1.63 |
| 2025-03-28 | IMCR | 29.58 | 34.9 | -65.6 | -1.63 |
| 2025-03-31 | IMCR | 29.67 | 34.9 | -68.7 | -1.63 |
| 2025-04-01 | IMCR | 28.63 | 34.9 | -63.4 | -1.63 |
| 2025-04-02 | IMCR | 29.43 | 34.9 | -72.3 | -1.63 |
| 2025-04-03 | IMCR | 29.04 | 34.9 | -66.6 | -1.63 |
| 2025-04-04 | IMCR | 27.23 | 34.9 | -59.7 | -1.63 |
| 2025-04-07 | IMCR | 26.25 | 34.9 | -63.5 | -1.63 |
| 2025-04-08 | IMCR | 24.53 | 33.4 | -59.0 | -1.63 |
| 2025-04-09 | IMCR | 26.07 | 33.4 | -77.9 | -1.63 |
| 2025-04-10 | IMCR | 25.88 | 33.4 | -67.6 | -1.63 |
| 2025-04-11 | IMCR | 26.57 | 33.4 | -72.1 | -1.65 |
| 2025-04-14 | IMCR | 26.92 | 33.4 | -70.3 | -1.65 |
| 2025-04-15 | IMCR | 27.31 | 32.9 | -70.6 | -1.61 |
| 2025-04-16 | IMCR | 27.90 | 33.0 | -71.7 | -1.61 |
| 2025-04-17 | IMCR | 28.41 | 33.0 | -71.4 | -1.61 |
| 2025-04-18 | IMCR | 28.41 | 33.0 | -68.7 | -1.61 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-20 | IMCR | 15.97 | 0.13 | 16.81 |
| 2025-03-21 | IMCR | 15.97 | 0.13 | 16.81 |
| 2025-03-24 | IMCR | 15.97 | 0.02 | 16.81 |
| 2025-03-25 | IMCR | 15.97 | 0.02 | 16.81 |
| 2025-03-26 | IMCR | 15.97 | 0.02 | 17.17 |
| 2025-03-27 | IMCR | 15.97 | 0.02 | 17.17 |
| 2025-03-28 | IMCR | 15.97 | 0.02 | 17.17 |
| 2025-03-31 | IMCR | 143.07 | 2.28 | 15.58 |
| 2025-04-01 | IMCR | 143.07 | 2.28 | 15.58 |
| 2025-04-02 | IMCR | 143.07 | 2.28 | 15.58 |
| 2025-04-03 | IMCR | 143.07 | 2.28 | 15.58 |
| 2025-04-04 | IMCR | 143.07 | 2.28 | 15.58 |
| 2025-04-07 | IMCR | 143.07 | 2.37 | 15.58 |
| 2025-04-08 | IMCR | 143.07 | 2.37 | 15.58 |
| 2025-04-09 | IMCR | 143.07 | 2.37 | 15.58 |
| 2025-04-10 | IMCR | 143.07 | 2.37 | 16.59 |
| 2025-04-11 | IMCR | 143.07 | 2.37 | 16.59 |
| 2025-04-14 | IMCR | 143.07 | 2.28 | 16.59 |
| 2025-04-15 | IMCR | 143.07 | 2.28 | 16.59 |
| 2025-04-16 | IMCR | 143.07 | 2.28 | 16.59 |
| 2025-04-17 | IMCR | 143.07 | 2.28 | 16.59 |
| 2025-04-18 | IMCR | 143.07 | 2.28 | 16.59 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.47
Avg. EPS Est. Current Quarter
-0.4
Avg. EPS Est. Next Quarter
-0.4
Insider Transactions
143.07
Institutional Transactions
2.28
Beta
0.76
Average Sales Estimate Current Quarter
86
Average Sales Estimate Next Quarter
88
Fair Value
20.86
Quality Score
49
Growth Score
57
Sentiment Score
72
Actual DrawDown %
63.1
Max Drawdown 5-Year %
Target Price
63.84
P/E
Forward P/E
PEG
P/S
4.58
P/B
3.97
P/Free Cash Flow
68.05
EPS
-1.03
Average EPS Est. Cur. Y
-1.61
EPS Next Y. (Est.)
-2
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-16.36
Relative Volume
0.61
Return on Equity vs Sector %
-34.1
Return on Equity vs Industry %
-20.8
EPS 1 7Days Diff
EPS 1 30Days Diff
0.02
EBIT Estimation
-68.7
Immunocore Holdings plcSector: Healthcare
Industry: Biotechnology
Employees: 493
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company's products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
stock quote shares IMCR – Immunocore Holdings plc ADR Stock Price stock today
news today IMCR – Immunocore Holdings plc ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch IMCR – Immunocore Holdings plc ADR yahoo finance google finance
stock history IMCR – Immunocore Holdings plc ADR invest stock market
stock prices IMCR premarket after hours
ticker IMCR fair value insiders trading